Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

PHASE2RecruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

February 28, 2025

Study Completion Date

February 29, 2028

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Furmonertinib

Furmonertinib 80mg QD

DRUG

Furmonertinib

Furmonertinib 80mg QD

DRUG

Furmonertinib/Pemetrexed/Carboplatin

Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.

DRUG

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab

Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.

Trial Locations (26)

Unknown

NOT_YET_RECRUITING

The First Hospital of Jilin University, Changchun

NOT_YET_RECRUITING

Sichuan Provincial People's Hospital, Chengdu

NOT_YET_RECRUITING

Dongguan People's Hospital, Dongguan

NOT_YET_RECRUITING

Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang People's hospital, Dongyang

NOT_YET_RECRUITING

The First People's Hospital of Foshan, Foshan

NOT_YET_RECRUITING

Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou

NOT_YET_RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

RECRUITING

Sun Yat-sen University cancer center, Guangzhou

NOT_YET_RECRUITING

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

NOT_YET_RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

NOT_YET_RECRUITING

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

NOT_YET_RECRUITING

Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou

NOT_YET_RECRUITING

Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen

NOT_YET_RECRUITING

Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua

NOT_YET_RECRUITING

Mianyang Central Hospital, Mianyang

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

NOT_YET_RECRUITING

Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang

NOT_YET_RECRUITING

Shijiazhuang People's hospital, Shijiazhuang

NOT_YET_RECRUITING

The Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi

NOT_YET_RECRUITING

The Third Affiliated Hospital of Wenzhou Medical University, Rui'an People's Hospital, Wenzhou

NOT_YET_RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

NOT_YET_RECRUITING

Yijishan Hospital, Wannan Medical College, Wuhu

NOT_YET_RECRUITING

Tangdu Hospital, Fourth Military Medical University, Xi'an

NOT_YET_RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

NOT_YET_RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

Allist Pharmaceuticals, Inc.

INDUSTRY

collaborator

GeneCast Biotechnology Co., Ltd.

INDUSTRY

lead

Sun Yat-sen University

OTHER

NCT05334277 - Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA | Biotech Hunter | Biotech Hunter